Scribe Therapeutics develops a platform for CRISPR-based genetic medicine. The company focuses on molecular engineering and integrated technologies for therapeutic use in genetic medicine.

Scribe Therapeutics

Scribe is enabling the creation of genetic medicines through its CRISPR by Design™ approach to genetic modification.

Prevail Therapeutics

Andreessen Horowitz

Avoro Capital Advisors

Avoro Ventures

Wellington Management

T. Rowe Price

Menlo Ventures

RA Capital Management

OrbiMed

Perceptive Advisors

Another summer, another annual beach day enjoyed with our Scribe family and friends! 

#NationalBeachDay #BayAreaBiotech

We will be at this week's Cold Spring Harbor Laboratory Genome Engineering: #CRISPR Frontiers meeting to share:

🧬 Our #CRISPRbyDesign approach
🧬 Advances in our epigenome editing platform and more

Looking forward to seeing you there to discuss how Scribe is engineering the future of epigenome editing!

#cshlcrispr24 #GeneEditing #EpigeneticEditing #GeneticMedicine #MolecularEngineering

Congratulations to our partners at Eli Lilly and Company on this new hub dedicated to accelerating genetic medicines!

What does the future of #healthcare look like? 

Our CEO Benjamin Oakes envisions one-and-done therapies that could treat conditions like cardiometabolic disease. In his TEDx Berkeley talk, he explains that engineering #CRISPR technology is key to developing effective genetic medicines for a broad range of diseases and helping underserved patients rewrite their genetic destinies.

Watch his full talk on the TEDx YouTube channel: https://lnkd.in/ghPuX9sq

TED Conferences University of California, Berkeley #GeneEditing #EpigeneticEditing #CRISPRbyDesign #MolecularEngineering #GeneticMedicine

In BioSpace, Greg Slabodkin highlights our "data-driven engineering approach—CRISPR by Design—that enables Scribe to build systems that allow for different genome editing outcomes than what’s possible with Cas9." 

Read more about our genome and epigenome editing tools for developing in vivo #CRISPR-based genetic medicines for broad patient populations ➡️ https://ow.ly/HROE50T1n6R 

#GeneEditing #EpigeneticEditing #CRISPRbyDesign #MolecularEngineering #GeneticMedicine

Next-generation #CRISPR technologies. In vivo therapies for sickle cell and cardiovascular disease. The future of genetic medicine, from gene editing to epigenetic editing.

At #AspenIdeasHealth, our CEO Benjamin Oakes, Nobel Laureate and Innovative Genomics Institute founder Jennifer Doudna, and CRISPR Therapeutics CEO Samarth Kulkarni discussed these topics and more.

Missed their Aspen Ideas discussion? Check out the video recording, now available on demand: https://lnkd.in/grDZ7wU7 

The Aspen Institute #CRISPRbyDesign #GeneEditing #MolecularEngineering #EpigeneticEditing #GeneticMedicine

news_impact_assignment_basic

key_people

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

merger_acquisitions

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Aug 31, 2024 11:16 AM	a0329bff
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general
crunchbase trigger	general	Nov 11, 2024 10:30 AM	33a5883d
crunchbase profile	general
li profile	general	Aug 31, 2024 11:16 AM	a9f6d2a3
translate crunchbase fundingrounds	general
peers	general	Aug 31, 2024 11:16 AM	3a665142
news basic	general	Aug 31, 2024 11:16 AM	5915a5cd
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

SCRI

COM:SCRIBETX

Scribe Therapeutics